Table 1.
Details of studies: design, diagnosis and measurement.
| Clinical Trial; (Country) | LSD dosage (n) | Control (n) | Blinding | Target condition/Inclusion criteria | Measures (time horizon) |
|---|---|---|---|---|---|
| Smart et al. (68); (Canada) | 800 mcg (10) | 60 mg ephedrine sulfate (10) No drug (10) |
Double-blind (not to “no drug” group) Independent assessors |
Alcoholics, “long history of excessive and uncontrolled drinking” (Male and female) |
Drinking History Questionnaire, Abstinence (6 months) Maudsley personality inventory, Haigh-Butler Q, Rorschach, Wechsler Adult Intellingence Scale |
| Hollister et al. (69); (USA) | 600 mcg (36) | 60 mg d- amphetamine (36) |
Double blind Independent assessors | Alcoholic Veterans, “acute alcoholic episode within 2 weeks of admission; all problem drinkers” (Male) |
Drinking Behaviour Scale (2, 6 months) |
| Ludwig et al. (70); (USA) | 3 mcg/kg 210 mcg mean (132) |
No drug (44) | Double blind until LSD session Independent assessors |
Alcoholics, “up to 4 previous admissions for treatment of alcoholism” (Male) |
Behaviour Rating Scale (6, 12 months) Abstinence (1, 3 months) California Psychological Inventory |
| Johnson (71); (Canada) | 300 mcg initial dose + 264 mcg mean (48) |
3.75 g Sodium Amytal + 30 mg Methedrine (22) / No drug (25) |
Single blind Independent assessors | Alcoholics in outpatient treatment (Male and female) | Abstinence, Drinking practice/consequences (12 months) Differential Personality Inventory, Quick test, Hidden Figures test |
| Bowen et al. (72); (USA) | 500 mcg (22) | 25 mcg LSD (22) No drug (15) |
Double-blind Independent assessors not mentioned |
Alcoholic Veterans under voluntary treatment for alcoholism (Male) | Adjustment scale (12 months) |
| Denson and Sydiaha (73); (Canada) | 50-300 mcg (163 mean) in subsequent dosage + 5 mg dextroamphetamine prior to LSD (25) |
No drug (26) | No attempt of blind Independent assessors | Alcoholic and neurotic patients (Male and female) | Eysenck Personality Inventory, IPAT Objective Anxiety Scale, Minnesota Multiphasic Personality Inventory, Lorr Multi-dimensional Rating Scale, Background Questionnaire for Non-Schizophrenic Patients (BFQNSP) (6, 12 months) |
| Pahnke et al. (62); (USA) | 450 mcg (73) | 50 mcg LSD (44) | Double-blind Independent assessors |
Alcoholics under voluntary treatment for alcoholism (Male) |
Drinking Behaviour Scale, Global Adjustment (6 months) |
| Tomsovic and Edwards (59); (USA) | 500 mcg (32) *non-schizophrenics | Usual treatment (45) *non-schizophrenics | Double-blind until LSD sesión Self-report assessment |
Alcoholics with 12 years average of problem drinking (Male) | Drinking Adjustment Scale (3, 6, 12 months) Blewett and Chwelos Scales |
| Savage and McCabe (74); (USA) | 300-450 mcg (37) | Usual treatment (37) |
No attempt of blind Independent assessors |
Narcotic addicts in Maryland correctional institutions (Male) |
Global adjustment rating scale, Abstinence (6, 12 months) |
| Savage et al. (65); (USA) | 350 mcg (31) | 50 mcg LSD (32) Usual treatment (33) |
Double-blind Independent assessors | Patients with psychoneurotic diagnosis, “depressed and anxious” (Male and female) | Psychiatric evaluation profile, Katz Adjustment Scale, Global adjustment scale (6 months) Block Design, Digit Span, Digit Symbol, Progressive Matrices, Embedded Figures, Benton Visual Retention Test, Minnesota Multiphasic Personality Inventory, Eysenck Personality Inventory, Personal Orientation Inventory |
| Gasser et al. (75); (Switzerland) | 200 mcg (8) | 20 mcg LSD (3) | Double blind Independent assessors | Anxiety associated with life- threatening deseases patients (Male and female) |
State-Trait Anxiety Inventory, European Cancer Quality of Life Questionnaire, SCL-90-R, Hospital Anxiety and Depression Scale, (1 week, 2, 12 months) |